AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05864157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRAC
Description: Metronome set to 85% on treadmill and 115% when walking overground
Study NCT05864157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dTRAC
Description: Metronome set around 85% on treadmill and around 115% when walking overground
Study NCT05297305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tornier Ascend Flex stem
Description: Reverse Total Shoulder Arthroplasty using onlay component (tray placed at top of humerus)
Study NCT06427941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-B2033
Description: Administered by intravenous infusion
Study NCT05297305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tornier Perform Stem Reverse+
Description: Reverse Total Shoulder Arthroplasty using inlay component (tray placed in humerus)
Study NCT06427941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered by intravenous infusion
Study NCT06189495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GenSci048
Description: 1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of Genakumab injection every 4 weeks according to their group.The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with Genakumab injection until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive Genakumab injection 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel
Study NCT06189495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GenSci048 placebo
Description: 1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of placebo every 4 weeks according to their group The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with placebo until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive placebo 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).~4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel)
Study NCT05727670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exposure of the tooth crown
Description: surgical exposure of the crown of a retentive tooth
Study NCT06206876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06206876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06206876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06206876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDX5 Degrader FL118
Description: Given PO
Study NCT06206876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05431010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Participants are required to be in the supine position. Routine disinfection first. Participants are then subjected to acupuncture and achieve deqi sensation at all acupuncture points. Four paired of acupuncture points (i.e. Biguan acupoints and Futu points; Yanglingquan acupoints and Zusanli acupoints, identical on both sides) are connected to the EA devices. EA parameter is set as sparse wave and frequency is 2Hz. The intensity of the EA is determined by the patients' tolerance. Needles will be left in place and each session of EA will last 30 minutes. Participants will undergo a total of 36 EA sessions, with the frequency of 3 sessions every week for 12 weeks.
Study NCT05431010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation Training
Description: The rehabilitation training group will be only treated with the Otago exercise program(OEP). Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia.~1. Exercise: including warm-up exercise (5 minutes) + resistance exercise (20 minutes) + balance training (5 minutes). Training intensity: 30 minutes a day, 3 times a week, once every other day, 12 weeks of training period; resistance exercise gradually increases the load.~2. Walking program: Take a walk. Activity intensity: 30 minutes each time, 2 times a week, combined with exercise (walking during the interval between exercise sessions), 12 weeks of training period
Study NCT05431010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Training
Description: The rehabilitation training group will be only treated with the Otago exercise program(OEP). Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia.~1. Exercise: including warm-up exercise (5 minutes) + resistance exercise (20 minutes) + balance training (5 minutes). Training intensity: 30 minutes a day, 3 times a week, once every other day, 12 weeks of training period; resistance exercise gradually increases the load.~2. Walking program: Take a walk. Activity intensity: 30 minutes each time, 2 times a week, combined with exercise (walking during the interval between exercise sessions), 12 weeks of training period
Study NCT04601987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding
Description: Counseling about the maternal health benefits of lactation.
Study NCT04601987 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smokefree Homes
Description: Counseling about the importance of smoke-free homes.
Study NCT05286151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythm discrimination
Description: Participants will complete a rhythm discrimination task once per year for 3 years.
Study NCT05750628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INE963
Description: oral INE963
Study NCT06284421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shore durometer
Description: The durometer will be held on the exterior of the lower uterine segment and fundus to measure the hardness reading at each location.
Study NCT06132763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hydration Intervention
Description: Teacher \& student ambassadors: serve as hydration role models, identify Hydration Heroes, monitor filter lights on hydration stations, \& update the water meter visual.~Kick-off event: event to kick off the hydration intervention to include water bottles distribution with a station to personalize, experiential activities, and information about the intervention.~Social marketing: student-developed marketing campaign Make water your superpower will be placed in high-traffic areas of the school. Hydration Headquarters will be located in the lunchroom displaying a water meter illustrating bottle refills from the school's hydration stations.~Behavioral reinforcement: on random days, students drinking water and/or with a water bottle will receive small incentives.~Education and outreach: Hydration Tip Sheets, hydration signage in classrooms, and hydration trivia on hydration stations. Teachers will deliver 1 hydration lesson per month that align with Standards of Learning.
Study NCT06132763 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control - Assessments Only
Description: Assessments only
Study NCT05227651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: IV infusion,Specified dose on specified days
Study NCT05750628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609 (Cipargamin)
Description: oral KAE609 (Cipargamin)
Study NCT05750628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SoC (Coartem)
Description: SoC (Coartem)
Study NCT05750628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLU156
Description: oral sachet KLU156 (KAF156 + lumefantrine)
Study NCT05698771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (NR)
Description: The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects . A total of 6 healthy individuals (3 men and 3 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using spectroscopic assays. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans.
Study NCT05698771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nicotinamide mononucleotide
Description: The NAD-brain study will perform a parallel assessment of NAD replenishment therapy (NRT) pharmacokinetics in the blood and brain of healthy human subjects. A total of 6 healthy individuals (3 men and 3 women) will undergo repeated blood sampling and 31P-MRS brain scans during two 20-day periods, each of which will start with 8 days of daily intake of Nicotinamide Riboside (NR) 600mg x 2, or Nicotinamide Mononucleotide (NMN) 600mg x 2. The two 20-day periods will be 14 days apart to allow for washout of the previous compound. Blood will be analyzed for NAD-metabolites using spectroscopic assays. By this approach we will measure the simultaneous change in NAD-metabolism over time in blood and brain and establish blood and brain pharmacokinetics for NRT in humans.
Study NCT05698771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (NR)
Description: A total of n=6 healthy individuals (3 men and 3 women) will receive NR 1200 mg per day for 4 weeks, followed by 3 weeks of washout. The individuals will undergo repeated blood sampling and 31P-MRS brain scans once per week during the 7 weeks period, Blood will be analyzed for NAD-metabolites using spectroscopic assays.
Study NCT05698771 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (NR)
Description: A total of n=6 individuals with Parkinson's disease (3 men and 3 women) will receive NR 1200 mg per day for 4 weeks, followed by 3 weeks of washout. The individuals will undergo repeated blood sampling and 31P-MRS brain scans once per week during the 7 weeks period, Blood will be analyzed for NAD-metabolites using spectroscopic assays.
Study NCT05881005 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: hepatic MRI
Description: Quantification of hepatic steatosis with RMI at the diagnosis (T0) and one year after remission (T1). The percentage of patients with complete resolution of hepatic steatosis on MRI will be determined.
Study NCT06033950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone
Description: Oral finerenone.
Study NCT06033950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo.
Study NCT04881240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR(Mem) T-cells
Description: Allogeneic CD19-CAR.CD45RA-negative T-cells Intravenous infusion
Study NCT04881240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
Study NCT04881240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.
Study NCT04881240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide.
Study NCT04881240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: A CliniMACS device is used to select donor T-cells for manufacturing of the memory CAR T-cell product.
Study NCT04881240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Leukapheresis is performed to collect the T cells that are needed to generate the CD19-CAR.CD45RA-negative T-cells product for the clinic study.
Study NCT06434506 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: No intervention
Study NCT06478745 — intervention group
Intervention type: OTHER
Intervention: Retrospective and prospective cohort
Description: * Retrospective study: Population-based retrospective cohort study with RWD. Patients ≥60 years old with 2 or more chronic diseases diagnosed before 01/01/2012, users of the public health system of the participating Autonomous Communities, will be included. Those who have had no contact with primary care defined as contact in a medical or nursing consultation in the previous two years (2010-2012) will be excluded.~* Prospective longitudinal observational open cohort study developed in the context of the MULTIPAP and LOXO studies.Patients over 65 years of age with multimorbidity (3 or more chronic pathologies) and polypharmacy (5 or more drugs taken during at least the last 3 months before inclusion in the study) under follow-up from primary care in Madrid, Aragon and Andalusia.
Study NCT06478745 — intervention group
Intervention type: OTHER
Intervention: Focus group, semi-structured interviews and Photovoice
Description: The participants will be people with multimorbidity over 60 years of age recruited from Primary Care centers in Spain. A theoretical sampling will be carried out. Data will be collected through video and audio recordings from a total of 16 focus groups and 20 interviews in 7 regions, and will finally be transcribed for a triangulated thematic analysis. Two groups will be carried out with participation-action research methodology - Photovoice.
Study NCT06478745 — intervention group
Intervention type: OTHER
Intervention: Systematic review
Description: No patient recruitment required
Study NCT04608448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin Topical Ointment
Description: 8% topical rapamycin ointment
Study NCT04608448 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Petrolatum ointment containing no active ingredient
Study NCT04847401 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: H. pylori stool antigen
Description: using H. pylori antigen kits in stool
Study NCT05121194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behaviour Therapy
Description: Group-based cognitive behaviour therapy (CBT) is an evidence-based treatment that allows service providers to interact with high volumes of individuals who need mental health support. CBT is the most well-researched and well-recognized of all psychotherapies, and is often considered the gold-standard in psychotherapy treatment. While CBT has shown efficacy in the treatment of a range of mental and substance use disorders, it has also been shown to be useful in building resiliency, being used as a tool to better cope during stressful life situations even among individuals who do not have an existing mental illness. Furthermore, research suggests that gains achieved in mental health during CBT are maintained long after treatment completion.
Study NCT05060315 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Remunity Pump for Remodulin
Description: Participants on the study will receive Remodulin via the Remunity Pump with dosing and titration managed at the discretion of the prescribing healthcare professional. Dosing and titration of Remodulin will in no way be influenced by the participation in this study or this protocol.
Study NCT05123443 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample provided
Description: Individuals who consent to provide a blood sample will be included in the cross-sectional genetics study.
Study NCT05123443 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 7-T MRI scan
Description: Individuals who consent to receive an additional 7-T MRI scan will be invited to the Sir Peter Mansfield Imaging Centre. This current MRI will be compared against the baseline 7-T scan performed between 2008 - 2012.
Study NCT05646316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05909891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient training
Description: A training booklet will be created by scanning the literature on iron deficiency anemia. The training booklet will be evaluated in terms of content and readability, according to the DISCERN measurement tool, while obtaining expert opinion.~The training period will be at least 35-40 minutes, taking into account the educational status of the patient and explaining the importance of compliance with the treatment. After the training, when the patients come to the routine check-ups in the 1st and 2nd months, the level of compliance with the treatment and the fatigue of the patients will be evaluated.
Study NCT05402436 — intervention group
Intervention type: OTHER
Intervention: A diagnosis of atypia as part of the English screening programme
Description: An atypia diagnosis of either ADH (including AIDEP), LISN (both ALH and LCIS) or FEA
Study NCT06053619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GaitTrainer and Virtual Reality
Description: Realization of Gait Trainer-assisted robot walking rehabilitation sessions without and with the addition of an immersive VR device. The proposed virtual stage will be a natural space (i.e. forest) of 360°. The subject will be able to explore the environment without moving. The created scene represents a straight path crossing a landscape composed of different natural elements. A fluid movement is obtained with the help of two sensors (trackers) of the HTC Vive device, placed at the level of the subject's feet. Moreover, thanks to these sensors the individual has a virtual representation of his lower limbs.~Post-stroke patients will perform 3 conventional sessions (Gait Trainer alone) and 3 sessions with the immersive VR device (Gait Trainer + VR).
Study NCT06284694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: See experimental arm description
Study NCT05715086 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopy
Description: Upfront ureteroscopy
Study NCT05490875 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid ultrasound
Description: Carotid ultrasound will be done to both sides of the neck to look at the carotid arteries.
Study NCT05490875 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: This optional blood draw could occur anytime from the time of enrollment on the study until 90 days after the research ultrasound.
Study NCT05490875 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Participants will complete a 15-minute survey about how acceptable participants find the ultrasound procedure, whether participants would be open to it in the future if a doctor thought it was necessary, whether participants would be open to getting treatment for artery problems, and how participants feel about their own risk of stroke.
Study NCT06052072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gradient Denervation System
Description: Pulmonary artery denervation (PADN) procedure using the Gradient Denervation System to ablate nerves within the pulmonary artery using ultrasonic ablation.
Study NCT05622968 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: Insertion of 18G Foley catheter into the cervical canal and inflating the balloon to 60 mls using sterile water
Study NCT05622968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravaginal prostaglandin E2
Description: Insertion of intravaginal Dinoprostone
Study NCT05622968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravaginal prostaglandin E2
Description: Insertion of intravaginal Dinoprostone
Study NCT04934293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Before proton therapy, virtual reality sessions will be performed.
Study NCT04735393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) administered for six weeks (QID for four weeks then BID for two weeks).
Study NCT04735393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Vehicle Ophthalmic Solution administered for six weeks (QID for four weeks then BID for two weeks).
Study NCT04735393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) administered for one year (QID for four weeks then BID for 11 months).